Last reviewed · How we verify
NCT05257850
Management of Breathlessness with High-flow Nasal Therapy or a Fan
NA trial testing High-flow nasal therapy in Breathlessness in 36 participants. Completed in 31 December 2024.
31 December 2024
Quick facts
| Lead sponsor | Tampere University Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 36 |
| Start date | 26 April 2022 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 2 locations across Finland |
Drugs / interventions tested
- High-flow nasal therapy
- Airflow directed to face by a fan
Conditions studied
- Breathlessness — all drugs for Breathlessness →
- Cancer — all drugs for Cancer →
Sponsor
Tampere University Hospital
Who can join
18 and older, any sex, with Breathlessness or Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Airflow directed to the face by a fan is shown to relief breathlessness in palliative care and some studies have suggested High-Flow nasal airflow therapy beneficial as well. However, these two treatments have not been compared. 40 patients with advanced cancer and breathlessness are recruited from Tampere University Hospital or Pirkanmaa Hospice. All patients are treated with two therapies: 1. High-Flow nasal airflow therapy with a nasal cannula and 2. airflow directed to the face by a fan. Both treatment periods last 30 minutes or as long as the patient wish to use the therapy. The effects of the therapies on breathlessness are compared by asking the subjective relief of breathlessness after each therapies. The study do not limit any other therapies used in the normal clinical care for the patients. Thus, all the other therapies the physicians taking care of the patient orders are permitted. Hopefully, the patients achieve relief for their breathlessness through the study treatments given in addition to their normal treatment. There are no significant risks related to the therapies, but they may cause some inconveniences such as mouth dryness. These possible side-effects of the therapies are asked as well.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Safety and Feasibility of Fan Therapy for Dyspnea: A Scoping Review.
Sato T, Taito S, Nakashima Y, Sakai K, et al · · 2023 · cited 4× · PMID 37608903 · DOI 10.7759/cureus.43668 -
Management of Dyspnea With High-Flow Nasal Air or Fan-A Randomized Controlled Crossover Trial.
Leivo-Korpela S, Rantala HA, Lehtimäki L, Piili RP, et al · · 2026 · cited 1× · PMID 40914402 · DOI 10.1016/j.jpainsymman.2025.08.033
Verify or expand the search:
- PubMed search for NCT05257850
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breathlessness
Currently open trials in the same condition.
- NCT07432893 — Assessing the Effectiveness of Large Language Model (LLM)-Enabled Nurse Treatment Planning in 2 Indian Districts · NA · recruiting
- NCT07281300 — Mindfulness-Oriented Respiratory Distress Symptom Intervention for Lung Cancer · NA · recruiting
Other Tampere University Hospital trials
Trials by the same sponsor.
- NCT07315568 — Couples and Microbial Diversity · not yet recruiting
- NCT07128992 — Need-driven Treatment of the Patients With Type 1 Diabetes · not yet recruiting
- NCT07042139 — No Reduction Compared to Closed Reduction for Distal Radius Fractures in Patients Over 65 or Older · NA · recruiting
- NCT07528833 — Health Effects of Mindfulness Based Stress Reduction Course in Treatment of Back Pain · NA · recruiting
- NCT06711796 — Measurement of Muscle Relaxation of the Hand in From Two Muscles and Two Hand Positions · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05257850 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tampere University Hospital
- Last refreshed: 31 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05257850.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing